These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label sanofi-aventis Allegra-D Fexofenadine NCT00547768 Urticaria Phase IV US: http://products.sanofi-aventis.us/allegra_D24/allegra_d24.html Other:Refer to local approved drug label Clinical Study Summary M016455A_4144 Comparative study evaluating the effects of fexofenadine HCI 180 mg with orange juice versus placebo with orange juice in a skin wheal and flare challenge model The summary result information on clinical trials is provided by the sanofi-aventis Group for informational purposes only and is not intended to promote any product or use. Summaries of clinical study results are intended to report the results of the study that were known at the time of the study’s completion. The summaries therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available, and the sanofi-aventis Group makes no representation or warranty of any kind as to the currency or completeness of the information contained in any summary, and disclaims all warranties, express or implied, with respect to such information. Healthcare Professionals should refer to the current approved product labeling for information on approved indications in their country. This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional. Company Study Study Report Back to Search Results